DELIVERY ORDER
Active75F40126F19005
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$1.6M
obligated · signed 2 weeks ago
DDI CLINICAL PHARMACOLOGY STUDY
Performance timeline
Start
Sep 30, 2026
End
Sep 29, 2027
with all options
Loading status
This contract is likely in the recompete window
Ends with all options: Sep 29, 2027
TRANQUIL CLINICAL AND RESEARCH CONSULTING SERVICES LLC
Contract 75F40126F19005
UEI
FWWJT8QCEDY4
Parent Company
TRANQUIL CLINICAL AND RESEARCH CONSULTING SERVICES LLC
Capabilities & Certifications
Headquarters Location
Congressional District: 36
Current Obligation
$1,592,481
Base + Exercised Options
$1,592,481
Total Ceiling Value
$1,592,481
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
PSC
GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; APPLIED RESEARCH
Place of Performance
Congressional District: 36
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Contract Vehicle
75F40125D00003
IDCDepartment of Health and Human Services
Award type: SINGLE AWARD
Solicitation procedures, competition exceptions, labor standards and account totals.